CHE Share Price | Chemed Corp. Stock Analysis & Recommendation

Q: How big is Chemed Corp.?

Market Cap: As of Jun 18, Chemed Corp. has a market capitalization of 19,624.38 million, categorizing it as a Mid Cap company.Recent Quarterly Performance: For the latest four quarters, Chemed Corp. reported net sales of 2,488.99 million and a net profit of 308.75 million.Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 1,118.99 million and total assets of 1,767.37 million.

Q: What does Chemed Corp. do?

Overview:Chemed Corp. operates in the hospital industry, providing hospice and palliative care services through its VITAS segment and plumbing services through its Roto-Rooter segment, and it falls within the mid-cap market category.Financial Snapshot:Most recent Net Sales: 647 Million (Quarterly Results - Mar 2025) Most recent Net Profit: 72 Million (Quarterly Results - Mar 2025) Market-cap: USD 19,624.38 Million (Mid Cap)Key Metrics:P/E: 65.00 Dividend Yield: 0.15% Debt Equity: -0.11 Return on Equity: 26.14% Price to Book: 16.61Contact Details:Address: 255 E 5th St Ste 2600, CINCINNATI OH: 45202-4138 Tel: 1 513 7626690 Website: http://www.chemed.com

Q: Is Chemed Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Chemed Corp. has moved from fair to very expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 65, a Price to Book Value of 16.99, and an EV to EBITDA ratio of 44.10, all of which are significantly higher than industry averages. In comparison, Universal Health Services, Inc. has a P/E ratio of 9.20 and an EV to EBITDA of 6.78, while National HealthCare Corp. shows a fair valuation with a P/E of 18.51 and an EV to EBITDA of 9.12.Recent performance shows that Chemed Corp. has underperformed against the S&P 500, with a year-to-date return of -16.84% compared to the S&P 500's 13.30%. This further reinforces the notion that the stock is overvalued given its high valuation ratios and poor relative performance.

Q: Is Chemed Corp. technically bullish or bearish?

As of 24 October 2025, the technical trend for Chemed Corp. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish signal from the daily moving averages and both weekly and monthly Bollinger Bands. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, indicating mixed signals across time frames. The KST is mildly bullish weekly but bearish monthly, while the Dow Theory presents a mildly bearish weekly and mildly bullish monthly stance. In terms of performance, Chemed Corp. has underperformed the S&P 500 across all multi-period returns, with a year-to-date return of -17.59% compared to the S&P 500's 15.47%, and a one-year return of -26.85% versus 16.90% for the index.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

37.42 k

Shareholding (Sep 2025)

FII

18.13%

Held by 225 FIIs

DII

40.45%

Held by 44 DIIs

Promoter

0.01%

How big is Chemed Corp.?

22-Jun-2025

As of Jun 18, Chemed Corp. has a market capitalization of $19.62 billion, with net sales of $2.49 billion and a net profit of $308.75 million over the last four quarters.

View full answer

What does Chemed Corp. do?

22-Jun-2025

Chemed Corp. operates in the hospital industry, offering hospice and palliative care services through VITAS and plumbing services via Roto-Rooter. As of March 2025, it reported net sales of $647 million and a market cap of approximately $19.62 billion.

View full answer

Who are in the management team of Chemed Corp.?

22-Jun-2025

As of March 2022, the management team of Chemed Corp. includes Mr. Kevin McNamara (CEO), Mr. George Walsh (Independent Chairman), and several independent directors: Mr. Thomas Hutton, Mr. Joel Gemunder, Mr. Patrick Grace, Mr. Walter Krebs, and Dr. Andrea Lindell.

View full answer

Is Chemed Corp. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Chemed Corp. is considered very expensive and overvalued with a P/E ratio of 65 and an EV to EBITDA of 44.10, significantly higher than industry averages, while underperforming the S&P 500 with a year-to-date return of -16.84%.

View full answer

Is Chemed Corp. technically bullish or bearish?

28-Oct-2025

As of October 24, 2025, Chemed Corp. is in a bearish trend, indicated by bearish daily moving averages and Bollinger Bands, with mixed signals from MACD and KST, and has significantly underperformed the S&P 500 with a year-to-date return of -17.59%.

View full answer

Compare Chemed Corp. with Similar Stocks

Universal Health Services, Inc.HCA Healthcare, Inc.Tenet Healthcare Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 28.67%

Company has a low Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 4.45% and Operating profit at 5.82% over the last 5 years

Flat results in Jun 25

With ROE of 26.14%, it has a very expensive valuation with a 16.99 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Hospital

Market cap

USD 6,424 Million (Small Cap)

P/E

65.00

Industry P/E

Dividend Yield

0.52%

Debt Equity

-0.08

Return on Equity

25.88%

Price to Book

5.97

Revenue and Profits:

Net Sales:

619 Million

(Quarterly Results - Jun 2025)

Net Profit:

52 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-25.64%

6 Months

-18.91%

1 Year

-18.55%

2 Years

-16.76%

3 Years

-4.48%

4 Years

-8.79%

5 Years

-1.1%

Chemed Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

4.45%

EBIT Growth (5y)

5.82%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt is too low

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

2.02

Tax Ratio

24.82%

Dividend Payout Ratio

9.05%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

39.17%

ROE (avg)

28.67%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

16.99

EV to EBIT

51.27

EV to EBITDA

44.10

EV to Capital Employed

18.98

EV to Sales

8.02

PEG Ratio

6.80

Dividend Yield

0.15%

ROCE (Latest)

37.01%

ROE (Latest)

26.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 124 Schemes (41.25%)

Foreign Institutions

Held by 225 Foreign Institutions (18.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 3.84% vs 7.60% in Jun 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -25.95% vs 32.77% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "618.80",
          "val2": "595.90",
          "chgp": "3.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "84.30",
          "val2": "103.80",
          "chgp": "-18.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "52.50",
          "val2": "70.90",
          "chgp": "-25.95%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "110.00%",
          "val2": "147.90%",
          "chgp": "-3.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.37% vs 6.06% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.83% vs 9.17% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,431.30",
          "val2": "2,264.40",
          "chgp": "7.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "436.00",
          "val2": "403.70",
          "chgp": "8.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.80",
          "val2": "3.10",
          "chgp": "-41.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.50",
          "val2": "-2.00",
          "chgp": "-225.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "302.00",
          "val2": "272.50",
          "chgp": "10.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "153.40%",
          "val2": "151.40%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

618.80

595.90

3.84%

Operating Profit (PBDIT) excl Other Income

84.30

103.80

-18.79%

Interest

0.40

Exceptional Items

0.00

Consolidate Net Profit

52.50

70.90

-25.95%

Operating Profit Margin (Excl OI)

110.00%

147.90%

-3.79%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 3.84% vs 7.60% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -25.95% vs 32.77% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,431.30

2,264.40

7.37%

Operating Profit (PBDIT) excl Other Income

436.00

403.70

8.00%

Interest

1.80

3.10

-41.94%

Exceptional Items

-6.50

-2.00

-225.00%

Consolidate Net Profit

302.00

272.50

10.83%

Operating Profit Margin (Excl OI)

153.40%

151.40%

0.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 7.37% vs 6.06% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 10.83% vs 9.17% in Dec 2023

All Annual Results

Company CV

About Chemed Corp.

Chemed Corp.

Hospital

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company's VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. VITAS is the provider of hospice services in an industry dominated primarily by small, non-profit, community-based hospices. VITAS provides hospice care to Medicare beneficiaries participating in these managed care programs. A portion of its VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration and other related services to both residential and commercial customers.

Company Coordinates

Company Details

255 E 5th St Ste 2600 , CINCINNATI OH : 45202-4138

Tel: 1 513 7626690

http://www.chemed.com

Registrar Details

Chemed Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Chemed Corp.?

Watch in Real-Time

What does Chemed Corp. do?

Who are in the management team of Chemed Corp.?

Is Chemed Corp. overvalued or undervalued?

Is Chemed Corp. technically bullish or bearish?

Compare Chemed Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

High Management Efficiency with a high ROE of 28.67%

Company has a low Debt to Equity ratio (avg) at times

Poor long term growth as Net Sales has grown by an annual rate of 4.45% and Operating profit at 5.82% over the last 5 years

Flat results in Jun 25

With ROE of 26.14%, it has a very expensive valuation with a 16.99 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Chemed Corp.

Company Coordinates